Jefferies Comments On Johnson & Johnson's Q1:11 Results

Loading...
Loading...
According to Jefferies, Johnson & Johnson's
JNJ
Q1:11 results and comments point toward improving pricing, volume, and utilization trends in select divisions. Jefferies reported that read-through is neutral-to-positive for competing companies in our universe including COV, BCR on the surgical end, and COO on the vision end. "Johnson & Johnson (JNJ, $60.46, NC) reported Q1:11 revenue of $16.2B (+1.8% y/y operational) and EPS of $1.25 (-3.1% y/y adjusted) versus Street expectations of $15.9B and $1.26. The company raised its EPS guidance to $4.90-$5.00, up from $4.80-$4.90 to reflect F/X impacts, strong pharma performance supported by recent launches, and other operational and capital restructuring benefits. Revised guidance does not include the after-tax gain of $910M realized in the quarter as a result of litigation settlements, nor does it reflect the pending $500M payment from Merck (MRK GR, €67.56, Hold - Holford) as a result of the recent REMICADE settlement.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsHealth CareJefferiesJohnson & JohnsonPharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...